Apis Pharma Starts Phase I studySinapis Pharma no erection.

Inc.apis Pharma Starts Phase I studySinapis Pharma, Inc no erection . Announced that its 14th first patients in a Phase I clinical study June 2010 were dosed. This study in human volunteers, designed to evaluate the safety, pharmacokinetics and absolute bioavailability of an intravenous infusion of methamphetamine. The first cohort, investigating shorter infusion times, all went well. Future cohorts evaluate longer infusion and higher drug doses. Source: Sinapis Pharma, Inc.

suhagra 100mg india

Sts Starts Clinical Research By Vascular – Targeted Photodynamic therapy for patients with localized prostate cancer – NYU Langone Medical Center is begun a clinical trial supply vascular directed photodynamic therapy to patients with localized prostate cancer. This new type used to is a minimally invasive A method light-activated medication on supply light energy shafts through laser at to damage prostate cancer cells. – This minimally invasive technical for localized prostate cancer the potential to give destroying to cancers without break or cause a potentially huge sexual, urinary tract or reproductive adverse effects offer, said Samir S. The James M. Neissa and Janet Riha Neissa an Associate Professor of Urologic Oncology and Director of the Department urologic Oncology at NYU Langone Medical Center and principal investigator for of the national, multi center clinical study tested of this technology. This procedure deals only with the portion of the prostate cancer cells , similar to a lumpectomy may be performed for breast cancer. When only one of the many personalized treatment options offered by the Smilow Complete Prostate Cancer Centre from NYU Langone. Medical Center The Centre offers a full range the latest treatment options for prostate cancer including: open or robotic prostatectomy, brachytherapy, external beam radiotherapy, cryosurgery and high – intensity focused ultrasound , a priority high – high – power sound waves prostate is now treat and in clinical studies at the medical center. This Phase I / II photodynamic therapy trial is opened diagnosis for both men with localized prostate cancer – determine through a biopsy and sophisticated imaging technologies – which have active surveillance select also known as a watchful-waiting during. Of the method laser fibers are via the prostate gland where cancer cells been identified to be positioned. Once in place , called photosensitiser medicament is , the patient is administered intravenously WST11 and circulates through blood flow for an additional ten minutes. Potential of fibers are then activated a specific wavelength of light to supply the prostate and twenty minutes. When light comes into contact with the medication in circulation, destroy the laser fiber the blood vessels of the tumor blood flow to the shutdown cancer. The patients are conducted one year after treatment with PSA screening up following each visit and MRI and biopsies for six months. Is focal treatment of prostate cancer with techniques such the photodynamic therapy is an emerging paradigm of since the has the the treatment of prostate cancer, an important issue to physicians and patients, said Dr. Taneja which also a member of NYU Cancer Institute.

Recent the European studies have shown photodynamic therapy success handled localized prostate carcinoma with minimum side effects. Those study will determine optimum dosage of the photosensitive drugs and optical – power wave and measure the results of patients and long-term cancer. To researchers believe the technology has the potential to any treating early stage prostate cancer and tumors in other organs of the body.